Beijing Tong Ren Tang Chinese Medicine (HKG:3613) First Half 2024 Results
Key Financial Results
- Revenue: HK$664.5m (down 18% from 1H 2023).
- Net income: HK$219.8m (down 17% from 1H 2023).
- Profit margin: 33% (in line with 1H 2023).
- EPS: HK$0.26 (down from HK$0.32 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Beijing Tong Ren Tang Chinese Medicine Earnings Insights
Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Hong Kong.
Performance of the Hong Kong Pharmaceuticals industry.
The company's shares are down 14% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Beijing Tong Ren Tang Chinese Medicine (at least 1 which is concerning), and understanding them should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.